Key Highlights

  • Entering the final weeks of September 2026, the backdrop for UK-listed healthcare and life-sciences companies is one of cautious normalisation rather than exuberance. The acute financing drought that weighed on small-cap biotechnology through the middle of the decade has eased from its worst, but Capital remains selective.
  • Diaceutics PLC (LSE:DXRX): On 8 September 2026 Diaceutics issued a Notice of Results and Presentations, signalling that its full first-half 2026 figures are imminent; for context, the equivalent H1 2025 results were published on 23 September 2025.
  • PureTech Health plc (LSE:PRTC): On 2 July 2026 the Founded Entity Celea Therapeutics completed a $180m financing round backed by RA Capital, Leaps by Bayer, PureTech and others.
  • Creo Medical Group plc (LSE:CREO): On 28 July 2026 Creo reported H1 2026 results showing Revenue of £3.2m, up around 45%, with the underlying operating loss narrowed to roughly £4.9m, a reduction of more than 25% year on year, and underlying costs cut by about 15%.
  • Arecor Therapeutics plc (LSE:AREC): Arecor’s FY2025 results, published on 13 April 2026 for the year to 31 December 2025, reported continuing revenue of £1.7m (2024: £1.6m) and an operating profit of £0.9m, a swing from a £5.2m loss in 2024 that was boosted by the Ligand Royalty deal.
  • Tristel plc (LSE:TSTL): On 22 July 2026 Tristel issued a FY2026 trading update for the year to 30 June 2026, reporting revenue of around £51.1m, up 10%, and adjusted pre-tax profit expected to be at least £11.5m, up 14%.
  • Scancell Holdings plc (LSE:SCLP): On 19 August 2026 Scancell received an MHRA Clinical Trial Authorisation for the Phase 3 registrational trial of iSCIB1+ in advanced melanoma.
  • ECO Animal Health Group plc (LSE:EAH): Full-year results for the year ended 31 March 2026, published on 15 July 2026, beat expectations.
  • Kromek Group plc (LSE:KMK): As at 11 September 2026, the FY26 full-year results for the year ended 30 April 2026 had not yet been published and are imminent; the prior-year finals were released on 16 September 2025.

The UK healthcare and life-sciences universe has rarely offered so broad a spread of Business models within a single thematic basket. The eight companies examined here range from a profitable infection-prevention manufacturer distributing chlorine dioxide chemistry to Mayo Clinic and Johns Hopkins, to a clinical-stage cancer-vaccine developer preparing a global Phase 3 trial, to a data-and-software group that commercialises diagnostics for eighteen of the world’s twenty largest pharmaceutical companies. What unites them is neither size nor stage but a shared orientation towards medical innovation listed on London’s markets, and the fact that each has produced concrete, verifiable newsflow during 2026 that warrants attention as the third quarter draws to a close.

A note on terminology is necessary at the outset. The word “FTSE” in the headline is deliberately broad editorial framing rather than a claim that any of these companies sits inside the FTSE 100 or FTSE 250. In truth the group straddles two distinct London venues. PureTech Health is the only Main Market name among them, dual-listed on the London Stock Exchange and Nasdaq, and is a reported constituent of the FTSE SmallCap index (on a secondary source), having earlier been removed from the FTSE 250 and FTSE 350 ex-investment-companies classifications. The remaining seven — Diaceutics, Creo Medical, Arecor Therapeutics, Tristel, Scancell, ECO Animal Health and Kromek — are all quoted on AIM, London’s growth market. None of the seven is verified as a current FTSE index constituent, though as AIM companies they are eligible for the FTSE AIM All-Share. Readers should treat any reference to FTSE membership accordingly.

The purpose of this article is observational, not directional. Several of these businesses carry substantial financing or clinical risk, and those risks are set out company by company. Investigational products are described as such throughout: a candidate in Phase 2 or Phase 3 trials is not an approved medicine, however encouraging its early data. Where the dossier underlying this piece does not confirm a figure, a rating or a date, that gap is stated rather than filled. With those caveats established, the following sections move from the macro backdrop into detailed profiles of each company, a near-term calendar and a concluding synthesis.

UK Biotech & Healthcare Market Backdrop

Entering the final weeks of September 2026, the backdrop for UK-listed healthcare and life-sciences companies is one of cautious normalisation rather than exuberance. The acute financing drought that weighed on small-cap biotechnology through the middle of the decade has eased from its worst, but capital remains selective. Investors have continued to reward demonstrable commercial traction, Recurring Revenue and visible paths to profitability, while applying heavier scrutiny to pre-revenue clinical-stage names whose progress depends on fresh funding. That bifurcation is visible across the group profiled here: the profitable, cash-generative businesses trade on a different footing from those still reliant on partnering income or Equity issuance to reach their next milestone.

Interest-rate expectations remain the single most important swing Factor for small-cap valuations. The long period of elevated rates raised the discount applied to distant cash flows, which bears most heavily on companies whose value sits years into the future — precisely the position of an immuno-oncology developer or an ultra-rapid insulin specialist. Any sustained shift in the rate outlook tends to disproportionately move the most speculative end of the market. Sterling’s level, meanwhile, matters directly to earnings: several of these companies derive the majority of their revenue overseas, in US dollars, euros and a spread of emerging-market currencies, so currency translation can flatter or flatten reported growth irrespective of underlying volume.

Thematically, several strands run through the sector. Immuno-oncology and therapeutic cancer vaccines continue to attract scientific and investor interest, with checkpoint-inhibitor combinations now a standard backbone against which novel agents are tested. Cell and gene therapy, precision medicine and companion diagnostics remain areas of structural growth, as treatment increasingly depends on identifying the right patient through testing before a targeted therapy is prescribed — a dynamic that underpins the diagnostic-commercialisation model. MedTech and advanced surgical energy devices are benefiting from a push towards less invasive, endoscopic procedures. Animal health, often overlooked, offers a more defensive profile tied to global protein demand, though it carries its own sensitivities to livestock-cycle Economics and to the regulatory tightening around antimicrobial use. Radiation detection and photon-counting imaging sit at the intersection of medtech and specialised industrial technology.

On the regulatory front, the interplay between the UK’s Medicines and Healthcare products Regulatory Agency and the US Food and Drug Administration shapes the timing of clinical programmes and product launches alike. For clinical-stage developers, clearance to begin a trial — whether an FDA investigational new drug acceptance or an MHRA clinical trial authorisation — is itself a material event. For commercial-stage medtech and disinfection businesses, FDA clearance is the gateway to the large US market, and the pace of US adoption frequently separates companies that have broken through from those still establishing a foothold. The NHS remains a significant domestic customer and reference point, though procurement budgets are constrained.

AIM small-cap conditions deserve particular mention, since seven of the eight companies here trade on that market. Liquidity at the smaller end of AIM can be thin, spreads wide and share prices volatile, which amplifies both the upside of positive newsflow and the downside of disappointments or dilutive fundraises. The market has nonetheless continued to function as a venue where genuinely innovative, capital-light or cash-generative businesses can build a following. The picture, in short, is neither uniformly buoyant nor uniformly bleak: it rewards evidence and punishes uncertainty, which makes the verifiable developments detailed below the most useful lens through which to assess each name.

Diaceutics PLC (LSE:DXRX)

Company overview

Diaceutics is a Northern Ireland-headquartered, AIM-quoted group that supplies data, software and services to accelerate the commercialisation of diagnostic tests and precision-medicine therapies. Its DXRX platform connects pharmaceutical companies with the laboratory and diagnostic ecosystem, and the business counts eighteen of the top twenty global pharmaceutical companies among its clients, supported by operations in the United States. It is not verified as a current FTSE index constituent, though as an AIM company it is eligible for the FTSE AIM All-Share. At 11 September 2026 its Market Capitalisation stood at roughly £124.75m, with the shares at 146.5p, down 0.65% on the day and approximately 18.6% below their 52-week high.

Latest September 2026 developments

On 8 September 2026 Diaceutics issued a Notice of Results and Presentations, signalling that its full first-half 2026 figures are imminent; for context, the equivalent H1 2025 results were published on 23 September 2025. Shortly before, on 20 August 2026, the company launched a next-generation-sequencing concordance study in Partnership with PCC, extending the practical application of its data platform.

Major 2026 developments

The defining update of the year so far came on 29 July 2026, when the trading update for the first half reported annual recurring revenue up 75% to £28.8m and H1 2026 revenue up 22% on a constant-currency basis to £17.5m. The order book stood at £43.7m, of which £15.7m was contracted for the second half, giving roughly 91% visibility on 2026 revenue. Adjusted EBITDA rose to £1.1m and gross Margin held around 87%, with the Balance Sheet debt-free on £8.1m of cash. Earlier, the FY2025 results on 26 May 2026 (for the year to 31 December 2025) showed revenue of £38.4m, up 20% as reported and 24% at constant currency, Gross Profit of £31.5m at an 82% margin, a return to operating profit of £43,000 against a £2.5m loss in 2024, adjusted EBITDA up 80% to £7.6m, pre-tax profit of £0.3m and basic Earnings of 0.11p per share. Annual recurring revenue reached £20.0m, up 19%, and the order book grew 56% to £38.9m. A second precision-medicine (“PMx”) partnership was signed in the fourth quarter of 2025, and the first PMx deal was expanded to a total contract value of £13.0m running through September 2028.

Products, pipeline and technology

The core asset is the DXRX platform, a data and analytics network that helps pharmaceutical clients understand testing pathways, identify eligible patients and improve the adoption of companion diagnostics. The PMx partnership model, layering recurring revenue on top of project work, is the strategic thrust: management has pointed to a 24-name PMx pipeline, of which eight were described as engaging.

Financial position

FY2025 cash finished at £7.3m, down from £12.7m, reflecting back-loaded revenue and extended customer payment terms; by the first half of 2026 cash had edged up to £8.1m, supported by a £2.0m undrawn overdraft facility. The company pays no Dividend and has not announced a buyback.

What investors may be watching

The full H1 2026 results, expected in late September 2026, are the immediate focus, alongside the conversion of the PMx pipeline and continued progression in recurring revenue and margin.

Key risks

Gross margins can be compressed by data costs in non-precision areas, a dynamic that cost roughly six percentage points in FY2025. The client base is concentrated among large pharmaceutical companies, lengthening payment terms can strain cash, and revenue ultimately depends on pharmaceutical research-and-development budgets.

PureTech Health plc (LSE:PRTC)

Company overview

PureTech Health is a clinical-stage biotherapeutics group dual-listed on the London Stock Exchange Main Market and Nasdaq, both under the ticker PRTC. It operates a “hub-and-spoke” model, developing and de-risking therapeutic programmes before advancing them through externally funded “Founded Entities”. It is a reported constituent of the FTSE SmallCap index, according to a secondary source (Adviser Rankings, September 2026), having earlier been removed from the FTSE 250 and the FTSE 350 ex-investment-companies index. At 10 September 2026 its market capitalisation was approximately £298.14m, with the shares at 121.6p, around 15% below their 52-week high. The company is best known for Karuna Therapeutics, whose schizophrenia drug Cobenfy was acquired by Bristol Myers Squibb in March 2024 in a deal worth roughly $1bn to PureTech, with retained royalties of around 2% on Cobenfy sales above $2bn.

Latest September 2026 developments

On 2 July 2026 the Founded Entity Celea Therapeutics completed a $180m financing round backed by RA Capital, Leaps by Bayer, PureTech and others. PureTech holds 35.4% of Celea on a fully diluted basis, having invested $30m with a further $70m reserved, alongside tiered royalties of 1–3%, up to $190m in milestones and 20% of sublicence income. Celea’s lead asset, the investigational deupirfenidone (LYT-100), entered the Phase 3 SURPASS-IPF head-to-head trial against pirfenidone in idiopathic pulmonary fibrosis, with a primary endpoint of forced vital capacity change at week 52, launching early in the third quarter of 2026. Half-year 2026 results are scheduled for 22 September 2026.

Major 2026 developments

At the full-year stage, PureTech-level cash stood at $277.1m at 31 December 2025 and $248.1m at 31 March 2026, with a runway described as extending at least through the end of 2028 and a stated intention to return a greater proportion of future cash to shareholders. In April 2026 Founded Entity Gallop Oncology reported positive initial topline Phase 1b data for the investigational LYT-200 in relapsed or refractory acute myeloid leukaemia and high-risk myelodysplastic syndromes, and is pursuing a registration-enabling MDS trial, with FDA Fast Track Designation in AML. In early May 2026 Founded Entity Seaport Therapeutics completed a Nasdaq IPO (SPTX) raising $254.9m gross through 14.16m shares at $18.00; PureTech retained roughly 16.69m Seaport shares but took no direct proceeds.

Products, pipeline and technology

The pipeline spans several non-consolidated entities: deupirfenidone/LYT-100 in Phase 3 for IPF (Celea, 35.4% owned); LYT-200 at the Phase 1b/Phase 2-enabling stage in AML and MDS (Gallop, wholly owned); Seaport’s GlyphAllo (SPT-300) in the Phase 2b BUOY-1 study for major depressive disorder, with topline data expected in the first half of 2027; and Vedanta’s VE303 in Phase 3 for recurrent Clostridioides difficile infection, in which PureTech holds around 4.2%.

Financial position

PureTech is effectively a cash-rich holding company. FY2025 revenue was about $4.66m, mainly Cobenfy royalties, with operating and net losses reflecting research-and-development and general costs; the H1 2025 operating loss was $(47.9)m. The cash runway extends into and through 2028.

What investors may be watching

Near-term attention centres on the 22 September 2026 half-year results, SURPASS-IPF progress, the design of Gallop’s registrational MDS trial, the BUOY-1 readout in 2027, capital-return decisions and the crystallisation of value from listed and Founded Entity stakes.

Key risks

The model carries binary clinical risk at Founded Entities; a large share of value is tied to non-consolidated equity stakes and their share prices, such as Seaport; dilution can occur within Founded Entities; a Leadership transition saw an interim chief executive and chair during 2025; and the net-asset-style valuation is inherently complex.

Creo Medical Group plc (LSE:CREO)

Company overview

Creo Medical is an AIM-quoted medtech company specialising in electrosurgery — advanced energy devices for flexible endoscopy and surgical ablation. It is not verified as a current FTSE index constituent, though it is eligible for the FTSE AIM All-Share. At 11 September 2026 its market capitalisation was around £56.7m, fluctuating in a roughly £56–61m range; in June 2026 the shares traded near 13.63p for a Market Value of about £61.2m. Its core technology is the CROMA electrosurgical platform combined with Kamaptive, an adaptive system marrying bipolar radiofrequency and microwave energy, supported by an accessory range including the Speedboat Notch, SpydrBlade Flex, MicroBlate Flex for lung ablation and MicroBlate Fine for pancreatic and liver applications. The company sells across the UK, Europe, the US and the rest of the world, with a growing presence in Latin America.

Latest September 2026 developments

On 28 July 2026 Creo reported H1 2026 results showing revenue of £3.2m, up around 45%, with the underlying operating loss narrowed to roughly £4.9m, a reduction of more than 25% year on year, and underlying costs cut by about 15%. The company completed equity and Debt financing during the period and flagged a planned sale of its remaining stake in Creo Medical SL (Spain) to strengthen liquidity. Full-year 2026 revenue-growth guidance was maintained at 50–60%.

Major 2026 developments

The FY2025 results on 22 May 2026 (for the year to 31 December 2025) showed revenue of £6.0m, up 50%, gross profit of £2.4m at a 40.0% margin, down from 47.5%, an operating loss of £(17.8)m (£(13.7)m underlying) and an underlying EBITDA loss of £(14.8)m. Cash stood at £12.4m and net Assets at £50.0m. The company had sold its 51% stake in CME to MicroTech in February 2025, generating £24.7m in net cash and a £26.2m profit, and secured £2m in conditional convertible Loan notes from the Development Bank of Wales after the period end. Directors flagged a going-concern material uncertainty, noting that without additional funding the company could not meet its liabilities within twelve months, though they expected to secure that funding. First-quarter FY26 revenue was up around 60% year on year, and Manufacturing has been outsourced to reduce costs.

Products & commercial strategy

The commercial strategy rests on driving adoption of CROMA and Kamaptive-enabled devices, expanding the accessory portfolio and pushing into higher-growth geographies, with Latin America a particular focus, while bearing down hard on the cost base.

Financial position

Creo remains loss-making, though the loss is narrowing. Cash was £12.4m at 31 December 2025 with low debt, and the going-concern caveat underscores the dependence on further funding.

What investors may be watching

Delivery on the 50–60% FY2026 revenue-growth target and the path to cash generation, completion of the Creo Medical SL disposal, Latin American approvals and adoption, and evidence of approaching break-even.

Key risks

The going-concern and funding dependence, with potential dilution, is the foremost risk, alongside gross-margin pressure, regulatory-approval timing in growth markets and execution of the commercial ramp.

Arecor Therapeutics plc (LSE:AREC)

Company overview

Arecor Therapeutics is a Cambridge-based specialty biopharmaceutical company built around its proprietary Arestat formulation platform, applied to insulins, GLP-1 agonists and biosimilars. It is AIM-quoted and not verified as a current FTSE index constituent, though eligible for the FTSE AIM All-Share. At 11 September 2026 its market capitalisation was approximately £28.88m, with the shares at 76.5p, unchanged on the day, and 37,756,601 shares in issue.

Latest developments

Arecor’s FY2025 results, published on 13 April 2026 for the year to 31 December 2025, reported continuing revenue of £1.7m (2024: £1.6m) and an operating profit of £0.9m, a swing from a £5.2m loss in 2024 that was boosted by the Ligand royalty deal. Cash and short-term investments stood at £6.1m (2024: £3.2m), with an explicit cash runway to May 2027. On the lead programme, the company reported positive feedback from an FDA Type C meeting on the Phase 2 design of its investigational AT278, with Phase 2 trial-enabling work progressing and the Phase 2 trial anticipated to start in the second half of 2026.

Major 2026 developments

AT278 is described as the only ultra-concentrated, ultra-rapid-acting insulin (500U/mL) in development, intended for automated insulin-delivery and patch-pump systems. A co-development agreement with Sequel Med Tech, struck in September 2025, is integrating AT278 into the twiist AID system, with the stated intent to broaden into full co-development and commercialisation. A royalty-financing arrangement with Ligand Pharmaceuticals in September 2025 provided $11m in total for AT220 biosimilar royalty rights, of which $7m was received upfront with $4m in milestones pending. The closure of the commercial Subsidiary Tetris Pharma reduced revenue but cut costs, three Arestat formulation collaborations are generating more than £1m in pre-licence revenue, and non-clinical pharmacokinetic studies for an oral GLP-1 programme were planned for 2026.

Products, pipeline and technology

The pipeline comprises AT278, with Phase 2 expected to start in the second half of 2026 and Phase 2-enabling work ongoing; AT247, a clinical-stage proprietary ultra-rapid insulin whose Patent protection was expanded in 2025; AT220, an Arestat biosimilar whose royalty rights were sold to Ligand; and a preclinical oral GLP-1 delivery platform.

Financial position

Arecor is a micro-cap with a small revenue base; the FY2025 operating profit was driven by one-off royalty income. Cash of £6.1m supports a runway to May 2027.

What investors may be watching

Securing the partner or financing needed to take AT278 into Phase 2 in the second half of 2026, any broadening of the Sequel deal, new Arestat partner agreements, oral-GLP-1 preclinical data and receipt of Ligand milestones.

Key risks

The limited cash runway to May 2027 and dependence on partnering or funding for the AT278 Phase 2 study are the central concerns, compounded by clinical and regulatory risk, a small revenue base and micro-cap liquidity.

Tristel plc (LSE:TSTL)

Company overview

Tristel is an AIM-quoted infection-prevention business built on proprietary chlorine dioxide disinfection chemistry. It is not verified as a current FTSE index constituent but is classified as a small-cap. Its core activity is the high-level disinfection of medical devices — notably Tristel ULT foam for ultrasound probes, Tristel OPH for ophthalmic instruments and the VISICLEAN detergent — alongside surface disinfection under the Cache Brand and veterinary and pharmaceutical products; roughly 88% of revenue comes from device decontamination. It sells across the UK, Europe and Australasia and increasingly in the United States via the FDA route, where adopters include the Mayo Clinic, Johns Hopkins and Memorial Sloan Kettering. At 10 September 2026 its market capitalisation was around £197.58m, with the shares at 411p, down about 0.6% on the day.

Latest September 2026 developments

On 22 July 2026 Tristel issued a FY2026 trading update for the year to 30 June 2026, reporting revenue of around £51.1m, up 10%, and adjusted pre-tax profit expected to be at least £11.5m, up 14%. Cash rose to £16.0m from £12.8m, the balance sheet remained debt-free, and the adjusted EBITDA margin sat above the company’s 25% long-term target. A change of leadership took effect on 1 August 2026, when Christopher Lee became chief executive, succeeding Matt Sassone; the appointment had been announced on 17 June 2026.

Major 2026 developments

The H1 FY2026 results on 2 March 2026 (for the six months to 31 December 2025) showed revenue of £25.65m, up 14%, a gross margin of 81%, operating profit of £4.89m, reported pre-tax profit of £4.96m, up 36%, and adjusted EBITDA of £7.34m, up 17% at a 29% margin. Basic earnings were 8.28p per share, and the Interim Dividend was held at 5.68p. Cash stood at £13.29m with no debt. US revenue reached £262,000, up 542% from a small base, with growth also in the Netherlands, France, Germany and Italy. Anna Wasyl was appointed chief financial officer, in-house wipe manufacturing was completed, and updated AIUM guidelines recognised chlorine dioxide for ultrasound-probe high-level disinfection.

Products & commercial strategy

Tristel’s commercial edge lies in its chlorine dioxide chemistry across Tristel ULT, the newly US-launched Tristel OPH, VISICLEAN and Cache. It is a commercial-stage, profitable and dividend-paying business, with the US market representing its principal growth avenue.

Financial position

Tristel is profitable, cash-generative and debt-free, with £16.0m of cash at the FY2026 year-end, gross margins above 80%, an EBITDA margin above 25% and a record of regular dividends.

What investors may be watching

The full FY2026 results, expected around autumn 2026, the new chief executive’s strategic direction, the US commercial ramp for OPH and ULT through the FDA pathway, and new geographic launches.

Key risks

The leadership transition, reliance on scaling a still-small US business, clearance timing for new US products, competition in high-level and surface disinfection, and currency exposure given that the majority of revenue is earned overseas.

Scancell Holdings plc (LSE:SCLP)

Company overview

Scancell Holdings is a Nottingham- and Oxford-based clinical-stage immuno-oncology company developing cancer vaccines through its ImmunoBody and Moditope platforms, alongside GlyMab antibodies. It is AIM-quoted and not verified as a current FTSE index constituent. Its market capitalisation was around £97.55m as of 24 July 2026, with the shares at 9.40p against a 52-week range of 7.86–29.50p; that pricing predates the 19 August 2026 MHRA news and should be treated as indicative. Its lead candidate is the investigational iSCIB1+, an ImmunoBody DNA Vaccine for advanced melanoma, supported by Modi-1 and Modi-2 (Moditope citrullinated-peptide vaccines), the earlier SCIB1, and GlyMab antibodies through the subsidiary GlyMab Therapeutics (lead SC134), together with a collaboration with Genmab on two licensed antibody candidates.

Latest September 2026 developments

On 19 August 2026 Scancell received an MHRA Clinical Trial Authorisation for the Phase 3 registrational trial of iSCIB1+ in advanced melanoma. The trial is designed as a randomised, double-blind, placebo-controlled adaptive study enrolling around 550 patients with stage III or IV unresectable melanoma across roughly 90 sites in the US, EU, UK, Canada and Australia, testing iSCIB1+ plus ipilimumab and nivolumab against placebo plus the same checkpoint inhibitors. Commencement is expected by the end of 2026, with initial progression-free-survival data targeted for the second half of 2028 and a Phase 2 neoadjuvant or adjuvant melanoma study planned for the first half of 2027. With the financial year ending 30 April, FY2026 preliminary results are likely imminent; the prior-year prelims were published on 11 September 2025.

Major 2026 developments

In January 2026 Scancell secured FDA clearance of its investigational new drug application for the global Phase 3 iSCIB1+ melanoma trial, and the candidate holds FDA Fast Track designation, accompanied by a SCOPE data update. Interim results on 29 January 2026 (for the six months to 31 October 2025) reported an operating loss of £8.9m, down from £10.5m, cash of £8.6m at 31 October 2025 (from £16.9m at 30 April 2025), a £3.0m research-and-development tax Credit received in December 2025, a cash runway to the second half of 2026 and net liabilities of £8.4m. The Phase 2 SCOPE study (140 patients) reported progression-free survival of 77% at 22 months and overall survival of 87.4% at 18 months with dual checkpoint inhibitors, while Modi-1 ModiFY Phase 2 data in head and neck and renal cancers was expected in the first half of 2026.

Products, pipeline and technology

iSCIB1+ is Phase 3-cleared following the January 2026 FDA IND and the 19 August 2026 MHRA CTA, with the trial expected to start by end-2026; Modi-1 is in a Phase 1/2 basket trial (ModiFY); SCIB1 is an earlier-generation asset; GlyMab’s SC134 is preclinical; and the Genmab-partnered antibodies are in preclinical development, with milestones anticipated in 2026.

Financial position

Scancell is clinical-stage and loss-making, with cash of £8.6m at 31 October 2025 and a stated runway only to the second half of 2026, making additional funding a near-term requirement, especially to finance a global Phase 3 trial; net liabilities were £8.4m.

What investors may be watching

The initiation of the iSCIB1+ Phase 3 trial by end-2026, Modi-1 ModiFY Phase 2 data, further SCOPE survival data, Genmab milestones, the FY2026 results and, critically, additional financing.

Key risks

The short cash runway against the cost of a global Phase 3 creates high financing and dilution risk; there is binary clinical-trial risk, reliance on partner milestones, and pronounced micro- and small-cap volatility, as the wide 52-week range illustrates.

ECO Animal Health Group plc (LSE:EAH)

Company overview

ECO Animal Health is an AIM-quoted animal-health company focused on veterinary pharmaceuticals and poultry vaccines. It is not verified as a current FTSE index constituent. Its flagship product is Aivlosin, a macrolide antibiotic for respiratory and enteric disease in pigs and poultry, sold in more than 70 markets, supported by a growing vaccine Franchise under the ECOVAXXIN brand. Its largest markets are North America, China and Japan, and Latin America. At 10 September 2026 its market capitalisation was around £66–70m, with the shares at roughly 98–103p.

Latest developments

Full-year results for the year ended 31 March 2026, published on 15 July 2026, beat expectations. Revenue rose to £87.5m from £79.6m, up 10% as reported and 14% at constant currency (£91.0m), with gross profit of £42.5m at a margin of 48.6%, up from 45.1%. Operating profit was £5.7m, adjusted EBITDA £8.5m (up 16%), pre-tax profit £5.4m (up 35%) and earnings 3.26p per share, up from 2.49p. Net cash stood at £25.4m, 39% of it held outside China, and no dividend was paid as the company reinvests in research and development.

Major 2026 developments

Regionally, North America grew 22% to £26.1m, Latin America 15% to £18.8m, and China and Japan 5% to £24.1m, with a softer fourth quarter reflecting pork-producer economics; South and South-East Asia fell 7% to £11.1m and Europe fell 2% to £4.8m. Banking facilities were renewed in June 2026 for five years, comprising a £10m revolving credit Facility and a £5m overdraft, both undrawn. Dr Andrew Winder was appointed Head of Business Development in May 2026, and non-executive director Frank Armstrong is stepping down at the September AGM. On vaccines, ECOVAXXIN MS, a Mycoplasma synoviae poultry vaccine, received EU Marketing authorisation in December 2025 and launched commercially in July 2026, while ECOVAXXIN MG received a favourable USDA safety assessment in March 2026; up to nine further products are targeted for US and EU approval within five to six years.

Products, pipeline and technology

The portfolio pairs the established Aivlosin antibiotic with an expanding vaccine pipeline. Management guided to FY2027 in line with market expectations, second-half weighted, described the FY2026 gross-margin gains as sustainable, and said it is assessing licensing and Acquisition opportunities.

Financial position

ECO Animal Health is profitable, with net cash of £25.4m and undrawn facilities, and it chooses to reinvest rather than pay a dividend.

What investors may be watching

US marketing approval for ECOVAXXIN MS, expected by the end of the 2026 calendar year, the EU commercial roll-out through Q3 2026 to Q1 2027, an R&D day in autumn 2026, further vaccine approvals, recovery in China and South/South-East Asia, and potential licensing or M&A.

Key risks

Reliance on the Aivlosin antibiotic amid pressure on antimicrobial use, regulatory and approval timing on the vaccine pipeline, currency exposure in China, Latin America and US dollars, livestock and pig-cycle economics and disease outbreaks, and softness in Asian markets.

Kromek Group plc (LSE:KMK)

Company overview

Kromek Group is a County Durham-based, AIM-quoted developer and manufacturer of cadmium-zinc-telluride (CZT) detector technology for medical imaging and CBRN security. It is not verified as a current FTSE index constituent. The business runs two divisions: Advanced Imaging, supplying CZT detectors for photon-counting CT and SPECT, including an enablement agreement with Siemens Healthineers; and CBRN Detection, providing radiation and nuclear detection to governments and security agencies, with distribution across 39 countries. Its market capitalisation was around £47.8m in mid-2026, on roughly 655.3m shares, with the shares recently at about 7.1–7.5p against a 52-week range of 4.85–12.80p.

Latest September 2026 developments

As at 11 September 2026, the FY26 full-year results for the year ended 30 April 2026 had not yet been published and are imminent; the prior-year finals were released on 16 September 2025. Recent announcements in August 2026 included “Delivery of Third Milestone and Grant of Options” on 6 August and a director share purchase on 3 August.

Major 2026 developments

A FY26 trading update on 12 May 2026 indicated that revenue and pre-tax profit were expected in line with market expectations, citing consensus of around £27.2m revenue and about £2.15m pre-tax profit, with both divisions growing year on year. Advanced Imaging showed good underlying growth excluding the Siemens enablement income, and CBRN grew despite slow government procurement; the company secured £8.8m of new orders in the second half, a significant proportion delivered before the year-end. Interim results on 20 January 2026 (for the six months to 31 October 2025) reported revenue of £15.0m, up from £3.7m, including £8.3m from Siemens licensing — Advanced Imaging contributing £10.8m and CBRN £4.3m, more than doubling. Gross profit was £10.8m at a 71.7% margin, operating profit £3.2m (against a £4.8m loss), adjusted EBITDA £6.0m (against a £2.3m loss) and pre-tax profit £3.1m. Cash was £1.2m at 31 October 2025, supported by a three-year £6.0m HSBC revolving credit facility (£1.0m drawn at period-end, plus £2.0m after the period). Contract wins included a £1.7m initial order under the UK Radiological Nuclear Detection Framework, a £250,000 18-month MoD Dstl contract and around £4.8m of year-to-date CBRN orders; Siemens enablement cash received to date was $30.0m, with around $7.5m remaining over roughly three years.

Products, pipeline and technology

Kromek’s technology base is its CZT detector expertise, applied to next-generation photon-counting CT and SPECT imaging and to radiation and nuclear threat detection for government and security customers.

Financial position

The company is moving into profitability, helped by Siemens enablement income, but balance-sheet cash is low at £1.2m at 31 October 2025, supported by the £6.0m HSBC facility.

What investors may be watching

The full FY2026 audited results, expected in September 2026, conversion of the CBRN government-contract pipeline, photon-counting CT adoption through Siemens and others, and further enablement milestone payments.

Key risks

Low cash and reliance on the debt facility and milestone timing, lumpy and government-dependent CBRN revenue with procurement delays, supply-chain and geopolitical exposure, concentration around the Siemens relationship, and micro-cap liquidity.

What Should Investors Watch During the Rest of September 2026?

The remaining weeks of September 2026 carry a concentrated run of scheduled corporate reporting across this group, which makes the near-term calendar unusually relevant.

Diaceutics is the most immediate. Its Notice of Results and Presentations on 8 September 2026 signalled that full first-half 2026 interim results are imminent; the equivalent H1 2025 figures were released on 23 September 2025, so a late-September publication is the reasonable expectation. Those results will show the detail behind the strong July trading update, including recurring-revenue and margin progression.

PureTech Health has a firm date: half-year 2026 results are scheduled for 22 September 2026. Attention there will fall on the cash position, the runway guidance, the progress of Celea’s Phase 3 SURPASS-IPF study and any further colour on capital-return intentions.

Kromek is expected to publish its full-year audited results for the year to 30 April 2026 during September 2026, with the prior-year finals having appeared on 16 September 2025. The figures will confirm whether the in-line trading update translated into the consensus revenue and pre-tax profit, and will show the year-end cash and debt position.

Scancell’s preliminary results are likely to fall near this window as well. With a financial year ending 30 April and the prior-year prelims published on 11 September 2025, FY2026 preliminary results may be imminent, though no exact date is confirmed in the underlying material. Any accompanying commentary on financing would be closely read given the stated runway to the second half of 2026.

Beyond these four scheduled or likely reporting events, the dossier does not confirm specific September dates for the other companies. Tristel’s full FY2026 results are expected around autumn 2026 rather than a confirmed September date; ECO Animal Health has already reported its full year, with the next catalysts being the September AGM and later vaccine approvals; Creo Medical and Arecor have also already reported, with their near-term focus on disposals, funding and clinical progression rather than imminent results. Where a precise date is not disclosed, none should be assumed.

Conclusion

Taken together, these eight companies illustrate how broad the UK-listed healthcare opportunity set has become, and how differently risk and reward are distributed across it. At one end sit the profitable, cash-generative businesses — Tristel, with its debt-free balance sheet, regular dividends and chlorine dioxide franchise now pushing into the United States; ECO Animal Health, whose better-than-expected full-year results and expanding vaccine pipeline give it a defensive animal-health profile; and Diaceutics, which returned to operating profit and posted a 75% jump in annual recurring revenue. At the other end are the clinical-stage developers whose value rests on data yet to be generated and trials yet to be funded — most clearly Scancell, which has cleared the regulatory hurdles for a global Phase 3 melanoma programme but must finance it against a runway stated only to the second half of 2026.

PureTech Health occupies a category of its own: a cash-rich Main Market Holding Company whose worth is tied to a portfolio of non-consolidated Founded Entities, from Celea’s Phase 3 idiopathic-pulmonary-fibrosis candidate to the listed stake in Seaport Therapeutics. Kromek and Creo Medical sit between the poles, each moving towards sustainable profitability while managing modest balance-sheet cash, with Kromek’s Siemens enablement income and Creo’s cost discipline central to their respective paths. Arecor, a micro-cap formulation specialist, depends on partnering and funding to advance its ultra-rapid insulin into Phase 2.

The common thread for observers is the density of verifiable milestones and reporting events clustered in and around September 2026 — Diaceutics’ interims, PureTech’s 22 September results, Kromek’s audited full-year figures and Scancell’s likely prelims — which makes this a period of unusually concentrated newsflow. Each company also carries clearly identifiable, and in several cases significant, risks: going-concern caveats, short cash runways, binary clinical outcomes, customer and partner concentration, currency exposure and the thin liquidity characteristic of the smaller end of AIM.

The companies are grouped here because they are worth watching, not because any outcome can be predicted; investigational candidates remain investigational until regulators decide otherwise, and the profitable names still face execution and competitive pressures. Readers considering any of these shares should weigh the company-specific risks set out above, note that prices and market capitalisations cited are as at the dates given, and recognise that small-cap healthcare investing demands patience and a tolerance for volatility. The sensible posture is to follow the evidence as it arrives through the autumn reporting season and to judge each business against its own stated milestones.